FDA approves refrigerated formulation of FluMist

The FDA has approved a new version of the inhalable FluMist that can be kept refrigerated instead of frozen. The regulatory approval is a notable win for the manufacturer, MedImmune, which has been confounded by difficulties in developing a market for the flu vaccine. MedImmune expects that the refrigerated reformulation will make it easier to keep the vaccine on hand and boost sales. The new vaccine will be available in August for the coming flu season.

- check out MedImmune's release on the approval
- here's the UPI's report on the approval

Related Articles:
MedImmune investor urges company to seek bidders. Report
MedImmune gets nod for new vaccine tech. Report
MedImmune touts new FluMist version. Report 

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.